SAKK 35/15:奥妥珠单抗联合维奈克拉治疗初治滤泡性淋巴瘤的1期试验
这项1期研究评估奥妥珠单抗联合维奈克拉在需全身治疗的初治1-3a级滤泡性淋巴瘤患者中的安全性、耐受性和初步疗效。25例患者入组,推荐2期剂量为维奈克拉800 mg每日一次连续6周期联合奥妥珠单抗,仅1例出现剂量限制性毒性(4级血小板减少)。CT评估的总体缓解率87.5%、完全缓解率25%;PET/CT评估分别为84.2%和68.4%;尽管观察到活性,结果不支持该联合方案在该人群进一步开发。
要点
- 推荐2期剂量:维奈克拉800 mg每日一次连续6周期,联合奥妥珠单抗1000 mg。
- 仅1例发生剂量限制性毒性,为首次奥妥珠单抗输注后4级血小板减少。
- CT评估总体缓解率87.5%、完全缓解率25%;PET/CT评估分别为84.2%和68.4%。
核心结论
- 尽管观察到抗肿瘤活性,本研究结果不支持该联合方案在初治1-3a级滤泡性淋巴瘤患者中进一步开发。
研究设计与样本
- 1期研究,评估奥妥珠单抗联合维奈克拉在需全身治疗的初治1-3a级滤泡性淋巴瘤患者中的安全性、耐受性和初步疗效。
- 共入组25例患者,评估两个维奈克拉剂量水平,并在推荐2期剂量下扩展队列。
主要发现
- 仅1例患者出现剂量限制性毒性,为首次奥妥珠单抗输注后4级血小板减少。
- 中性粒细胞减少是至少可能归因于研究治疗的≥3级不良事件中最常见者。
- 第6周期后CT可评估24例,总体缓解率87.5%(95% CI,67.6%至97.3%),完全缓解率25%(95% CI,9.8%至46.7%)。
- PET/CT可评估19例,总体缓解率84.2%(95% CI,60.4%至96.6%),完全缓解率68.4%(95% CI,43.4%至87.4%)。
- CT可评估患者1年无进展生存率77.8%(95% CI,54.6%至90.1%),PET/CT可评估患者79%(95% CI,47.9%至92.7%);30个月无进展生存率CT评估73.2%(95% CI,49.8%至87.0%),PET/CT评估79.0%(95% CI,47.9%至92.7%)。
关键数值与推荐
- 推荐2期剂量:维奈克拉800 mg每日一次连续6周期,从第1周期第2天开始;奥妥珠单抗1000 mg于第1周期第1、8、15天及第2至6周期第1天给药,随后奥妥珠单抗维持治疗每2个月一次持续2年。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出,尽管观察到活性,结果不支持该联合方案在该患者人群进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 1 study evaluated safety, tolerability, and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two DLs of venetoclax were evaluated with an expansion cohort at the recommended phase 2 dose. Twenty-five patients were enrolled. The recommended phase 2 dose was venetoclax 800 mg OD continuously for 6 cycles starting on day 2 of cycle 1, with obinutuzumab 1000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 to 6, followed by obinutuzumab maintenance every 2 months for 2 years. Only 1 patient had a DLT consisting of grade 4 thrombocytopenia after the first obinutuzumab infusion. Neutropenia was the most common adverse event of grade ≥3 at least possibly attributed to study treatment. Twenty-four patients were evaluable for response after cycle 6 by computed tomography (CT) and 19 by positron emission tomography/CT (PET/CT): overall and complete response rates were 87.5% (95% CI, 67.6% to 97.3%) and 25% (95% CI, 9.8% to 46.7%) in the CT-evaluated patients and 84.2% (95% CI, 60.4% to 96.6%) and 68.4% (95% CI, 43.4% to 87.4%), respectively, in the PET/CT-evaluated patients. One-year progression-free survival was 77.8% (95% CI, 54.6% to 90.1%) and 79% (95% CI, 47.9% to 92.7%) for CT and PET/CT-evaluable patients, respectively, whereas progression-free survival at 30 months was 73.2% (95% CI, 49.8%, 87.0%) as assessed by CT and 79.0% (95% CI, 47.9%, 92.7%) by PET/CT. Despite the activity observed, our results do not support further development of the combination in this patient population. This trial was registered at www.clinicaltrials.gov as #NCT02877550.
引用
- Stathis A, Mey U, Schär S, et al. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv. 2022. PMID: 35537101. doi:10.1182/bloodadvances.2021006520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。